Will warfarin soon be passé? new approaches to stroke prevention in atrial fibrillation

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 1, 2008, Pages 18-27

  Hammwöhner, Matthias ^a   Goette, Andreas ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Anticoagulation; Atrial fibrillation; Pathophysiology; Pharmacology; Stroke

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ARC 1779; ARGATROBAN; ATI 5923; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING INHIBITOR; DABIGATRAN ETEXILATE; DU 176B; DX 90605; ENOXAPARIN; FONDAPARINUX; HIRULOG; IDRAPARINUX; LEPIRUDIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; NEMATODE ANTICOAGULANT PROTEIN 5; NEMATODE ANTICOAGULANT PROTEIN C2; OTAMIXABAN; PRT 054021; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RIVAROXABAN; SRR 126517E; SSR 34006; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN; YM 150; ANGIOTENSIN RECEPTOR; BLOOD CLOTTING FACTOR 10A; DRUG DERIVATIVE; FIBRINOLYTIC AGENT; THROMBIN;

ACUTE CORONARY SYNDROME; ARTERY THROMBOSIS; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; EMBOLISM; FOOD; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STROKE; THROMBOEMBOLISM; THROMBOGENESIS; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; DRUG ANTAGONISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; RECEPTORS, ANGIOTENSIN; STROKE; THROMBIN; WARFARIN;

EID: 55949127463     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318177e1f2     Document Type: Review

References (93)

1. Wolf PA, Dawber TR, Thomas HE Jr, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28:973-977.
2. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
3. Bogousslavsky J, Garazi S, Jeanrenaud X, et al. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology. 1996;46:1301-1305.
4. Jorgensen HS, Nakayama H, Reith J, et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke. 1996;27:1765-1769.
5. Arndt M, Lendeckel U, Rocken C, et al. Altered expression of ADAMs (A Disintegrin And Metalloproteinase) in fibrillating human atria. Circulation. 2002;105:720-725.
6. Bukowska A, Lendeckel U, Hirte D, et al. Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation. Cell Mol Life Sci. 2006;63:333-342.
7. Cai H, Li Z, Goette A, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation. 2002; 106:2854-2858.
8. Dobrev D. Electrical remodeling in atrial fibrillation. Herz. 2006;31: 108-112.
9. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation. 1996;94:2968-2974.
10. Goette A, Lendeckel U, Klein HU. Signal transduction systems and atrial fibrillation. Cardiovasc Res. 2002;54:247-258.
11. Hammwöhner M, D'Alessandro A, Dobrev D, et al. New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers. Herzschrittmacherther Elektrophysiol. 2006;17:73-80.
12. Blackshear JL, Safford RE. AFFIRM and RACE trials: implications for the management of atrial fibrillation. Card Electrophysiol Rev. 2003;7: 366-369.
13. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347: 1825-1833.
14. Dudley SC Jr, Hoch NE, McCann LA, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation. 2005;112:1266-1273.
15. Minamino T, Kitakaze M, Sato H, et al. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vasc Biol. 1997;17:3191-3195.
16. Bukowska A, Schild L, Keilhoff G, et al. Verapamil attenuates mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia. Exp Biol Med (Maywood). 2008;233:558-574.
17. Goette A, Bukowska A, Lendeckel U, et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation. 2008;117:732-742.
18. Lendeckel U, Muller C, Rocken C, et al. Expression of opioid receptor subtypes and their ligands in fibrillating human atria. Pacing Clin Electrophysiol. 2005;28:S275-S279.
19. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001;104: 174-180.
20. Goette A, Ittenson A, Hoffmanns P, et al. Increased expression of P-selectin in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol. 2000;23:1872-1875.
21. daCunha V, Tham DM, Martin-McNulty B, et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis. 2005;178:9-17.
22. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98:121-128.
23. Kamiyama N. Expression of cell adhesion molecules and the appearance of adherent leukocytes on the left atrial endothelium with atrial fibrillation: rabbit experimental model. Jpn Circ J. 1998;62:837-843.
24. Wang HD, Xu S, Johns DG, et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res. 2001;88:947-953.
25. Campbell DJ, Woodward M, Chalmers JP, et al. Soluble vascular cell adhesion molecule 1 and N-terminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease. Arch Neurol. 2006;63:60-65.
26. Kawamura T, Umemura T, Kanai A, et al. Soluble adhesion molecules and C-reactive protein in the progression of silent cerebral infarction in patients with type 2 diabetes mellitus. Metabolism. 2006;55:461-466.
27. Hammwöhner M, Ittenson A, Dierkes J, et al. Platelet expression of CD40/CD40 ligand and its relation to inflammatory markers and adhesion molecules in patients with atrial fibrillation. Exp Biol Med (Maywood). 2007;232:581-589.
28. Yamashita T, Sekiguchi A, Iwasaki YK, et al. Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation. 2003;108:2450-2452.
29. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-719.
30. Conway DS, Pearce LA, Chin BS, et al. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation. 2002;106:1962-1967.
31. Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol. 2001; 37:1436-1442.
32. Conway DS, Pearce LA, Chin BS, et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 2003;107:3141-3145.
33. Li-Saw-Hee FL, Blann AD, Gurney D, et al. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J. 2001;22:1741-1747.
34. Kageyama S, Yamamoto H, Nagano M, et al. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol. 1997;122:165-171.
35. Gilbert JC, Feo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007;116:2678-2686.
36. Hoffman M, Monroe DM, III. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958-965.
37. Monroe DM, Hoffman M, Roberts HR. Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. Blood Coagul Fibrinolysis. 1996;7:459-464.
38. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22:1381-1389.
39. Cirino G, Cicala C, Bucci MR, et al. Thrombin functions as an inflammatory mediator through activation of its receptor. J Exp Med. 1996;183: 821-827.
40. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257-e354.
41. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003; 3:221-230.
42. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008; 358:999-1008.
43. Agnelli G. Current issues in anticoagulation. Pathophysiol Haemost Thromb. 2005;34 Suppl 1:2-9.
44. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-2692.
45. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
46. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
47. Ferro JM. Cardioembolic stroke: an update. Lancet Neurol. 2003;2: 177-188.
48. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131: 927-934.
49. McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. rch Intern Med. 2001;161:2458-2463.
50. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007;121: 23-34.
51. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14:1745-1751.
52. Chu K, Wu SM, Stanley T, et al. A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest. 1996;98: 1619-1625.
53. Ulrich S, Brand B, Speich R, et al. Congenital hypersensitivity to vitamin K antagonists due to FIX propeptide mutation at locus -10: a (not so) rare cause of bleeding under oral anticoagulant therapy in Switzerland. Swiss Med Wkly. 2008;138:100-107.
54. Siguret V. Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy. Pathol Biol (Paris). 2007;55: 295-298.
55. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis. 2008;25:45-51.
56. Bauer KA. New anticoagulants: anti IIa vs anti Xa-is one better? Thromb Thrombolysis. 2006;21:67-72.
57. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028-1040.
58. Tulinsky A. Molecular Interactions of Thrombin. Semin Thromb Hemost. 1996;22:117-124.
59. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990; 86:385-391.
60. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost. 2005;3: 1843-1853.
61. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008;29:155-165.
62. Hammwöhner M, D'Alessandro A, Wolfram O, et al. New pharmacologic approaches to prevent thromboembolism in patients with atrial fibrillation. Curr Vasc Pharmacol. 2007;5:211-219.
63. Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002;45:1757-1766.
64. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation. 2007;116:552-560.
65. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64:292-303.
66. Caprini JA, Hwang E, Hantel S, et al. The oral direct thrombin inhibitor, dabigatran etexilate, is effective and safe for prevention of major venous thrombembolism following major orthopedic surgery. J Thromb Haemost. 2007;5:OW-050:
67. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949-956.
68. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-2185.
69. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100: 1419-1426.
70. Rai R, Sprengeler PA, Elrod KC, et al. Perspectives on factor Xa inhibition. Curr Med Chem. 2001;8:101-119.
71. Rapezzi C, Biagini E, Branzi A. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J. 2008;29:277-278.
72. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354: 1464-1476.
73. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295: 1519-1530.
74. Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet. 2002;41(Suppl 2):1-9.
75. Hjelm R, Schedin-Weiss S. High affinity interaction between a synthetic, highly negatively charged pentasaccharide and alpha- or beta-antithrombin is predominantly due to nonionic interactions. Biochemistry. 2007;46: 3378-3384.
76. Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008;371:315-321.
77. Bayer EA, Skutelsky E, Wilchek M. The avidin-biotin complex in affinity cytochemistry. Methods Enzymol. 1979;62:308-315.
78. Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis. 2008;25:53-60.
79. Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost. 2006;96:274-284.
80. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007;5: 2368-2375.
81. Weinz C, Buetehorn U, Daehler HP, et al. Pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor - in rats and dogs. Xenobiotica. 2005;35:891-910.
82. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3:514-521.
83. Fujii Y, Takahashi M, Morita H, et al. Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant. Drug Metab Pharmacokinet. 2007;22:26-32.
84. Paccaly A, Frick A, Rohatagi S, et al. Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure. J Clin Pharmacol. 2006; 46:37-44.
85. Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27:1238-1247.
86. Agnelli G, Haas S, Ginsberg JS, et al. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost. 2007;5:746-753.
87. Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost. 2007;98: 883-888.
88. Rios-Steiner JL, Murakami MT, Tulinsky A, et al. Active and exo-site inhibition of human factor Xa: structure of des-Gla factor Xa inhibited by NAP5, a potent nematode anticoagulant protein from Ancylostoma caninum. J Mol Biol. 2007;371:774-786.
89. Eriksson BI, Dahl OE, Lassen MR, et al. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008;6:457-463.
90. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-247.
91. Giugliano RP, Wiviott SD, Stone PH, et al. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol. 2007;49:2398-2407.
92. Moons AH, Peters RJ, Bijsterveld NR, et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol. 2003;41:2147-2153.
93. Lee A, Agnelli G, Buller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001;104:74-78.